Ovarian Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Ovarian Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month15 studies across 14 companies, in the next 180 days.
August 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| CORT | Corcept Therapeutics | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersNCT06906341Progression-Free Survival (PFS) | Phase 2 | Recruiting | Aug 2026 | ≤ 11 d | 2026-07-16 |
| NRIX | Nurix Therapeutics, Inc. | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | 2026-08-31 | in 11 d | 2025-09-09 |
| RADX | Radiopharm Theranostics, Ltd | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsNCT05799274Radiation dosimetry of RAD301 | Phase 1 | Recruiting | Aug 2026 | ≤ 11 d | 2026-07-17 |
October 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| TEM | Tempus AI | Tempus Priority Study: A Pan-tumor Observational StudyNCT05179824observationalCreate robust data set of health information | — | Active, not recruiting | 2026-10-19 | in 60 d | 2025-05-06 |
| IDYA | IDEAYA Biosciences | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDE | Phase 1 | Active, not recruiting | Oct 2026 | ≤ 72 d | 2026-07-13 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in ItalyNCT07407062observationalFRα - Positive Status | — | Recruiting | Nov 2026 | ≤ 102 d | 2026-07-27 |
December 2026 9
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| TCRX | TScan Therapeutics, Inc. | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid TumorsNCT05973487Evaluate the safety of monotherapy and T- Plex combination TCR-Ts | Phase 1 | Active, not recruiting | 2026-12-30 | in 132 d | 2025-11-17 |
| BCAX | Bicara Therapeutics | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsNCT04429542Safety of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs | Phase 1 | Recruiting | 2026-12-31 | in 133 d | 2025-08-15 |
| CNTX | Context Therapeutics Inc. | CT-95 in Advanced Cancers Associated With Mesothelin ExpressionNCT06756035Determine the MTD or RD of CT-95 [Safety and Tolerability] | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-06-12 |
| GNLX | Genelux Corporation | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)NCT05281471Progression-free survival (PFS) by RECIST 1.1 in the Intention-to-Treat (ITT) population (all randomized participants regardless of whether they received any dose of treatment) | Phase 3 | Recruiting | Dec 2026 | ≤ 133 d | 2026-07-10 |
| JAZZ | Jazz Pharmaceuticals | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | 2026-12-31 | in 133 d | 2026-07-10 |
| MNPR | Monopar Therapeutics | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsNCT06617169Identify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2025-05-21 |
| NXTC | NextCure, Inc. | A Phase 1 Study of LNCB74 in Advanced Solid TumorsNCT06774963Evaluate the safety and tolerability of LNCB74 | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2025-12-16 |
| PFE | Pfizer | PF-07104091 as a Single Agent and in Combination TherapyNCT04553133Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle | Phase 2 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-05-06 |
| PFE | Pfizer | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingNCT05059522Number of participants with adverse events leading to permanent discontinuation of study intervention | Phase 3 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-06-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Ovarian Cancer
most recently updated first306 studies match. Showing the first 100 of 306 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesNCT04644068The number of subjects with adverse events/serious adverse events | Phase 1/2 | Active, not recruiting | Drug: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant | Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5 | 702 | 2020-11-12 | 2027-05-28 | in 281 d | 2026-08-19 |
| BOLD | Boundless Bio, Inc. | $65M | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsNCT05827614Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-355 as a single agent and in combination with each of the following agents: erlotinib, futibatinib, or BBI-825 | Phase 1 | Terminatedsponsor's stated reason: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal. | Drug: BBI-355, Erlotinib, Futibatinib, BBI-825 | Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer | 85 | 2023-03-24 | 2026-03-17actual | — | 2026-08-19 |
| AZN | AstraZeneca | — | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion) | Phase 1/2 | Recruiting | Drug: AZD6750, rilvegostomig | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma | 120 | 2025-07-29 | 2029-10-02 | in 1,139 d | 2026-08-19 |
| WHWK | Whitehawk Therapeutics, Inc. | $271M | A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.NCT07470853Determine Maximum Tolerated Dose (MTD) | Phase 1 | Recruiting | Drug: HWK-016, MUCIN-16-targeted ADC, Bevacizumab | PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer | 265 | 2026-03-15 | Feb 2028 | ≤ 558 d | 2026-08-18 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsNCT04895709Incidence of adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig | Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms | 1,109 | 2021-05-27 | 2031-08-31 | in 1,837 d | 2026-08-17 |
| NXTC | NextCure, Inc. | $30M | A Phase I Study of SIM0505 in Participants With Advanced Solid TumorsNCT06792552dose escalation: Dose-limiting toxicity (DLT) | Phase 1 | Recruiting | Drug: SIM0505 for injection, SIM0505 for injection | Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma (Prcc), Uterine Serous Carcinoma (USC), NSCLC (Non-small Cell Lung Cancer), Primary Peritoneal Cancer | 738 | 2025-02-26 | Feb 2028 | ≤ 558 d | 2026-08-17 |
| VSTM | Verastem, Inc. | $673M | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerNCT06072781Progression Free Survival (PFS) per blinded independent central review (BICR) | Phase 3 | Recruiting | Drug: avutometinib, Defactinib, Pegylated liposomal doxorubicin, Paclitaxel, Letrozole, Anastrozole | Low Grade Serous Ovarian Cancer | 270 | 2024-03-18 | 2028-10-15 | in 787 d | 2026-08-14 |
| ABBV | AbbVie | $457.5B | A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.NCT06890338Objective Response (OR) by Independent Central Review (ICR) | Phase 2 | Recruiting | Drug: Carboplatin, Mirvetuximab Soravtansine, Bevacizumab | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant | 140 | 2025-11-21 | Feb 2030 | ≤ 1,288 d | 2026-08-14 |
| AZN | AstraZeneca | — | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211Objective response rate (ORR) | Phase 2 | Recruiting | Drug: Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin | Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer | 454 | 2022-09-06 | 2027-10-01 | in 407 d | 2026-08-13 |
| NXTC | NextCure, Inc. | $30M | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsNCT05572684results2026-08-13Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 | Phase 1/2 | Terminatedsponsor's stated reason: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. | Drug: NC410, pembrolizumab | Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer | 97 | 2022-10-06 | 2025-04-30actual | — | 2026-08-13 |
| XNCR | Xencor, Inc. | $1.9B | Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid TumorsNCT07593092Incidence of Adverse Events | Phase 1 | Recruiting | Biological: XmAb541, XmAb808 | Ovarian Cancer | 90 | 2026-06-30 | Dec 2028 | ≤ 864 d | 2026-08-13 |
| AZN | AstraZeneca | — | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesNCT05123482The number of patients with adverse events | Phase 1/2 | Recruiting | Drug: AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), AZD8205 in combination with AZD9574, AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936) | Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer | 460 | 2021-10-18 | 2027-09-29 | in 405 d | 2026-08-12 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerNCT06787612Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessment | Phase 2 | Recruiting | Drug: Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, REGN10597 | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 297 | 2025-05-28 | 2028-06-30 | in 680 d | 2026-08-12 |
| ZNTL | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | $264M | A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein ExpressionNCT07546500Progression free survival (PFS) per RECIST v1.1 as assessed by Investigator | Phase 3 | Recruiting | Drug: Investigator's choice of Chemotherapy, Azenosertib | Ovarian Cancer | 420 | 2026-04-17 | 2028-05-31 | in 650 d | 2026-08-12 |
| MGNX | MacroGenics | $261M | A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest. | Phase 1 | Recruiting | Biological: MGC026 Dose Escalation, MGC026 Dose for Expansion | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC) | 250 | 2024-03-06 | May 2028 | ≤ 650 d | 2026-08-11 |
| PMVP | PMV Pharmaceuticals, Inc | $66M | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt | Phase 1/2 | Recruiting | Drug: rezatapopt, pembrolizumab | Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer | 300 | 2020-10-29 | 2026-08-15 | — | 2026-08-10 |
| 4568.T | Daiichi Sankyo | $31.7B | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478Number of Participants With Objective Response Rate Assessed by Investigator Following HER3-DXd Monotherapy (All Cohorts Except Prostate Cancer Cohort) | Phase 2 | Recruiting | Drug: HER3-DXd | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer | 740 | 2024-02-26 | 2027-09-01 | in 377 d | 2026-08-10 |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.NCT07755436Treatment-Emergent Adverse Event (TEAE) | Phase 1 | Recruiting | Drug: ARR-002 | Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer, Metastatic Endometrial Cancer | 180 | 2026-07-23 | Aug 2027 | ≤ 376 d | 2026-08-10 |
| 051910.KS | LG Chem | $13.7B | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C MutationNCT07752875Phase 1: Number of participants with dose-limiting toxicities (DLTs) | Phase 1/2 | Not yet recruiting | Drug: LG00313112 | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Pancreatic Cancer, Locally Advanced Unresectable or Metastatic Solid Tumor | 250 | 2026-12-01 | 2032-10-31 | in 2,264 d | 2026-08-07 |
| NVCT | Nuvectis Pharma, Inc. | $681M | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian CancerNCT05226507Part A: Number of patients with treatment related adverse events, clinical laboratory abnormalities, dose limiting toxicities | Phase 1 | Terminatedsponsor's stated reason: Study terminated due to various reasons impacting the feasibility of future clinical development | Drug: NXP800 | Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation | 45 | 2021-12-31 | 2025-01-01actual | — | 2026-08-06 |
| AZN | AstraZeneca | — | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationNCT05877599Module 1, Part 1: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours | Phase 1 | Recruiting | Biological: NT-175 | Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS) | 45 | 2023-07-12 | 2029-07-31 | in 1,076 d | 2026-08-06 |
| INCY | Incyte Corporation | $24.7B | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionNCT07023627Objective Response by IRC | Phase 2 | Recruiting | Drug: INCB123667 | Ovarian Cancer | 160 | 2025-11-12 | 2027-04-27 | in 250 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4337713 in Participants With FAP-Positive Solid TumorsNCT07213791Phase 1a: Percentage of Participants with Dose Limited Toxicity (DLT) Toxicities | Phase 1 | Recruiting | Drug: LY4337713 | Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma | 241 | 2025-10-22 | Jul 2028 | ≤ 711 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerNCT07213804Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator | Phase 3 | Recruiting | Drug: Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin | Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis | 1,630 | 2025-10-22 | Nov 2028 | ≤ 833 d | 2026-08-06 |
| INCY | Incyte Corporation | $24.7B | Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionNCT07214779Progression-Free Survival (PFS) by BICR | Phase 3 | Recruiting | Drug: INCB123667, Investigator's choice of chemotherapy | Ovarian Cancer | 466 | 2025-12-09 | 2028-11-15 | in 818 d | 2026-08-06 |
| AZN | AstraZeneca | — | Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian CancerNCT01081951results2012-12-10Progression Free Survival (PFS) | Phase 2 | Active, not recruiting | Drug: olaparib, paclitaxel, carboplatin, paclitaxel, Drug: carboplatin | Ovarian Cancer | 162 | 2010-02-04 | 2011-10-10actual | — | 2026-08-05 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031 | Phase 1 | Recruiting | Drug: LY4052031 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 420 | 2024-07-01 | May 2027 | ≤ 284 d | 2026-08-05 |
| WHWK | Whitehawk Therapeutics, Inc. | $271M | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid TumorsNCT07444814Determine Maximum Tolerated Dose (MTD) | Phase 1 | Recruiting | Drug: HWK-007 | Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR Wt NSCLC, Platinum Resistant Ovarian Cancer, PROC | 226 | 2025-12-19 | Oct 2028 | ≤ 803 d | 2026-08-05 |
| VSTM | Verastem, Inc. | $673M | Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)NCT07747506Duration of Treatment Exposure to Avutometinib in Combination With Defactinib | Phase 2 | Not yet recruiting | Drug: avutometinib + defactininb combination | Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | 2 | 2026-08-03 | 2027-08-01 | in 346 d | 2026-08-05 |
| IMNN | Imunon | $9M | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal CancerNCT05739981Minimal Residual Disease | Phase 1/2 | Recruiting | Drug: Paclitaxel, Carboplatin, Bevacizumab, IMNN-001 | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 30 | 2023-02-10 | 2027-06-30 | in 314 d | 2026-08-04 |
| IMNN | Imunon | $9M | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerNCT06915025Overall Survival | Phase 3 | Recruiting | Drug: IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin, Olaparib, Niraparib | Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 500 | 2025-07-09 | 2032-10-31 | in 2,264 d | 2026-08-04 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian CancerNCT07059845Substudy 1, 2, and 3: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) (any grade, Grade >= 3) | Phase 2 | Recruiting | Drug: Mirvetuximab Soravtansine, Bevacizumab, Carboplatin | Ovarian Cancer | 400 | 2025-11-13 | Jan 2029 | ≤ 895 d | 2026-08-04 |
| AZN | AstraZeneca | — | Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of HistologyNCT07167433observationalDescription of socio-demographic characteristics | — | Recruiting | — | Ovarian Cancer | 250 | 2025-09-19 | 2027-06-30 | in 314 d | 2026-08-04 |
| ABBV | AbbVie | $457.5B | Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) CountriesNCT07539844observationalFolate Receptor Alpha (FRa) Overexpression Immunohistochemistry (IHC)in Each Participating Sites (Local and Central) | — | Recruiting | — | Ovarian Cancer | 1,000 | 2026-07-02 | Mar 2027 | ≤ 223 d | 2026-07-31 |
| ALLR | Allarity Therapeutics | $21M | Clinical Pre-screening Protocol for Ovarian CancerNCT03877796observationalIdentification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug | — | Recruiting | Device: Drug Response Predictor® (DRP) | Ovarian Cancer | 60 | 2019-04-11 | Jun 2027 | ≤ 314 d | 2026-07-30 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersNCT05891171Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Drug: AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin | Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC) | 40 | 2023-10-13 | Sep 2027 | ≤ 406 d | 2026-07-30 |
| AZN | AstraZeneca | — | Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyNCT01874353results2018-02-07Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1) | Phase 3 | Active, not recruiting | Drug: Olaparib 300mg tablets, Placebo to match olaparib 300mg | Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy | 327 | 2013-09-03 | 2016-09-19actual | — | 2026-07-29 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in ItalyNCT07407062observationalFRα - Positive Status | — | Recruiting | — | Cancer - Ovarian | 200 | 2026-06-26 | Nov 2026 | ≤ 102 d | 2026-07-27 |
| AAPG | Ascentage Pharma Group Inc. | — | APG-2449 in Patients With Advanced Solid TumorsNCT03917043Maximum Tolerated Dose (MTD) | Phase 1 | Recruiting | Drug: APG-2449 | Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma | 165 | 2019-05-27 | Dec 2027 | ≤ 498 d | 2026-07-23 |
| AZN | AstraZeneca | — | 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)NCT04553926observationalSafety (adverse events (AEs), serious AEs (SAEs), adverse drug reactions(ADRs), serious ADRs (SADRs), unexpected AEs/ADRs) | — | Completed | — | Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer | 661 | 2021-02-01 | 2025-07-11actual | — | 2026-07-23 |
| AZN | AstraZeneca | — | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsNCT05797168Number of participants with adverse events/serious adverse events | Phase 1/2 | Recruiting | Drug: Torvutatug samrotecan, Saruparib, Bevacizumab, Carboplatin, Palacaparib, Pembrolizumab | Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma | 602 | 2023-06-05 | 2028-08-04 | in 715 d | 2026-07-23 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersNCT03564340Number of participants with Dose-limiting toxicity (DLTs) for ubamatamab monotherapy | Phase 1/2 | Recruiting | Drug: Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab | Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer | 890 | 2018-05-21 | 2027-05-10 | in 263 d | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2NCT06003231Confirmed Objective Response Rate (ORR) per Response Evaluation in Solid Tumors version 1.1 (RECIST v1.1) by investigator assessment | Phase 2 | Active, not recruiting | Drug: disitamab vedotin | Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms | 120 | 2023-11-14 | 2026-03-27actual | — | 2026-07-22 |
| AZN | AstraZeneca | — | DESTINY-PANTUMOUR04NCT07124000observationalReal world response rate (rwRR) | — | Recruiting | Drug: Trastuzumab deruxtecan | Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer | 100 | 2025-09-18 | 2028-03-30 | in 588 d | 2026-07-22 |
| AZN | AstraZeneca | — | AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerNCT07218809Progression free Survival (PFS) | Phase 3 | Recruiting | Drug: AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel, Pegylated liposomal Doxorubicin (PLD), Topotecan | Epithelial Ovarian Cancer | 1,100 | 2025-12-29 | 2028-11-17 | in 820 d | 2026-07-21 |
| RADX | Radiopharm Theranostics, Ltd | — | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsNCT05799274Radiation dosimetry of RAD301 | Phase 1 | Recruiting | Drug: RAD301 ([68Ga]-RAD301) | Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrial Cancer, Ovarian Cancer | 9 | 2023-11-09 | Aug 2026 | ≤ 11 d | 2026-07-17 |
| CORT | Corcept Therapeutics | $12.8B | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersNCT06906341Progression-Free Survival (PFS) | Phase 2 | Recruiting | Drug: Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer | 270 | 2025-04-11 | Aug 2026 | ≤ 11 d | 2026-07-16 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian CancerNCT07278336Number of Participants with Adverse Events (AE) | Phase 1 | Recruiting | Drug: ABBV-901, Bevacizumab | Ovarian Cancer | 219 | 2025-11-27 | Jan 2029 | ≤ 895 d | 2026-07-15 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsNCT05787587Part 1 (Dose Escalation): To characterize the safety and tolerability of IDE161 monotherapy or in combination with pembrolizumab to determine the MTD and/or RDE | Phase 1 | Active, not recruiting | Drug: IDE-161, Pembrolizumab | Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC | 216 | 2023-04-18 | Oct 2026 | ≤ 72 d | 2026-07-13 |
| AZN | AstraZeneca | — | Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian CancerNCT04830709observationalprogression-free survival (PFS) | — | Active, not recruiting | — | Ovarian Cancer | 752 | 2021-06-15 | 2033-03-31 | in 2,415 d | 2026-07-10 |
| GNLX | Genelux Corporation | $118M | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)NCT05281471Progression-free survival (PFS) by RECIST 1.1 in the Intention-to-Treat (ITT) population (all randomized participants regardless of whether they received any dose of treatment) | Phase 3 | Recruiting | Biological: olvimulogene nanivacirepvec · Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar) | Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma | 186 | 2022-08-31 | Dec 2026 | ≤ 133 d | 2026-07-10 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR | Phase 2 | Recruiting | Drug: Zanidatamab | Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression | 200 | 2025-01-14 | 2026-12-31 | in 133 d | 2026-07-10 |
| BMY | Bristol-Myers Squibb | $134.9B | A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsNCT06997029Number of Participants With Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: BMS-986500, Palbociclib, Fulvestrant | Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer | 234 | 2025-08-01 | 2028-12-14 | in 847 d | 2026-07-10 |
| LLY | Eli Lilly and Company | $1.15T | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsNCT02009449results2026-07-09Number of Participants With TEAEs and SAEs Observed During the Study of Pegilodecakin | Phase 1 | Completed | Drug: Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin | Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer | 353 | 2013-11-15 | 2019-02-19actual | — | 2026-07-09 |
| AZN | AstraZeneca | — | Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese PatientsNCT04560452observationalNumber and percentage of patients with AEs as well as number of AE events as assessed by CTCAE | — | Completed | — | Ovarian Cancer, Prostate Cancer | 1,018 | 2021-03-15 | 2025-09-05actual | — | 2026-07-08 |
| AZN | AstraZeneca | — | Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer PatientsNCT03737643results2026-06-09Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set | Phase 3 | Active, not recruiting | Drug: Bevacizumab, Durvalumab, Olaparib, Placebo olaparib, Durvalumab placebo, Carboplatin+Paclitaxel | Advanced Ovarian Cancer | 1,407 | 2019-01-04 | 2025-03-17actual | — | 2026-07-07 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of SGN-MesoC2 in Advanced Solid TumorsNCT06466187Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Drug: PF-08052666 | Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial | 19 | 2024-08-02 | 2026-05-27actual | — | 2026-07-07 |
| AZN | AstraZeneca | — | Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube CancerNCT07402915Area under curve from time 0 to time 17 days (AUC0-17days) | Phase 1 | Recruiting | Drug: AZD5335, Itraconazole | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal | 24 | 2026-01-26 | 2027-10-15 | in 421 d | 2026-07-07 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin | Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms | 1,006 | 2020-06-08 | 2027-06-16 | in 300 d | 2026-07-06 |
| CATX | Perspective Therapeutics | $366M | Lead-212 PSV359 Therapy for Patients With Solid TumorsNCT06710756Determination of safety and tolerability of [203Pb]Pb-PSV359 | Phase 1/2 | Recruiting | Drug: [203Pb]Pb-PSV359, [212Pb]Pb-PSV359 | Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma | 112 | 2025-04-28 | 2028-01-31 | in 529 d | 2026-07-06 |
| 4568.T | Daiichi Sankyo | $31.7B | Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)NCT06819007Progression Free Survival by Blinded Independent Central Review (BICR) in the HER2 IHC 3+/2+ population | Phase 3 | Recruiting | Drug: Trastuzumab Deruxtecan, Bevacizumab | Ovarian Cancer | 582 | 2025-03-19 | 2028-11-01 | in 804 d | 2026-07-02 |
| IBRX | ImmunityBio, Inc. | $8.2B | A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian CancerNCT06710288Evaluate Progression Free Survival (PFS) | Phase 2 | Recruiting | Drug: Gemcitabine · Biological: N-803, M-CENK | Platinum-resistant Ovarian Cancer | 20 | 2024-11-06 | May 2027 | ≤ 284 d | 2026-07-01 |
| 3402.T | Toray Industries, Inc | $12.6B | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsNCT03872947Frequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0 | Phase 1 | Active, not recruiting | Biological: TRK-950, TRK-950, TRK-950 · Drug: Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD | Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer | 138 | 2019-04-26 | Jun 2026 | — | 2026-06-23 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanNCT05005403Number of Participants with Adverse Events (AE) | Phase 1 | Recruiting | Drug: Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan | Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer | 694 | 2021-11-01 | Jul 2027 | ≤ 345 d | 2026-06-23 |
| PFE | Pfizer | $155.3B | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingNCT05059522Number of participants with adverse events leading to permanent discontinuation of study intervention | Phase 3 | Active, not recruiting | Drug: Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, PF04518600 | Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors | 77 | 2021-09-29 | 2026-12-31 | in 133 d | 2026-06-22 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4170156 in Participants With Selected Advanced Solid TumorsNCT06400472Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156 | Phase 1 | Recruiting | Drug: LY4170156, bevacizumab, carboplatin, Itraconazole, pembrolizumab | Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms | 495 | 2024-05-20 | Feb 2027 | ≤ 192 d | 2026-06-18 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesNCT07503808Safety and tolerability of IDE034 in Part 1 dose escalation | Phase 1 | Recruiting | Drug: IDE034 | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer | 150 | 2026-02-24 | 2027-07-30 | in 344 d | 2026-06-18 |
| CNTX | Context Therapeutics Inc. | $49M | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid TumorsNCT06515613Incidence of Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: CTIM-76 | Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer | 156 | 2024-07-10 | 2028-05-31 | in 650 d | 2026-06-16 |
| GNLX | Genelux Corporation | $118M | Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian CancerNCT02759588results2026-06-12Number of Participants With Related Treatment-emergent Adverse Event [Safety and Tolerability] (Phase 1b) | Phase 1/2 | Completed | Biological: Olvi-Vec · Drug: Platinum-doublet with or without bevacizumab | Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer | 46 | May 2016 | 2021-12-31actual | — | 2026-06-12 |
| AZN | AstraZeneca | — | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibNCT04421963Safety follow up | Phase 3 | Active, not recruiting | Drug: Olaparib | Ovarian Cancer, Breast Cancer | 185 | 2020-08-04 | 2027-04-06 | in 229 d | 2026-06-12 |
| ABBV | AbbVie | $457.5B | A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha ExpressionNCT06365853Number of Participants With MIRV-related Corneal TEAEs (≥ Grade 2) in Asymptomatic Participants | Phase 2 | Recruiting | Drug: Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops | Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive | 100 | 2024-07-29 | Jun 2026 | — | 2026-06-12 |
| CNTX | Context Therapeutics Inc. | $49M | CT-95 in Advanced Cancers Associated With Mesothelin ExpressionNCT06756035Determine the MTD or RD of CT-95 [Safety and Tolerability] | Phase 1 | Recruiting | Drug: CT-95 | Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable, Mesothelin-expressing Advanced Cancers, Mesothelin-positive Advanced Malignant Solid Tumors, Colorectal Cancer | 70 | 2025-03-31 | Dec 2026 | ≤ 133 d | 2026-06-12 |
| XNCR | Xencor, Inc. | $1.9B | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid TumorsNCT06276491Incidence of adverse events | Phase 1 | Recruiting | Biological: XmAb541 | Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor | 282 | 2024-04-04 | Dec 2027 | ≤ 498 d | 2026-06-11 |
| RXRX | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | $1.7B | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsNCT07517198Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: EXS74539 | Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC) | 40 | 2026-04-13 | Mar 2029 | ≤ 954 d | 2026-06-10 |
| PFE | Pfizer | $155.3B | Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.NCT04881045Number of participants with dose limiting toxicities (DLTs) in Dose Escalation (Part 1) | Phase 1 | Completed | Biological: PF-07257876 | Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer | 29 | 2021-08-18 | 2023-10-24actual | — | 2026-06-02 |
| ABBV | AbbVie | $457.5B | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerNCT05445778Assess Progression-free survival (PFS) | Phase 3 | Active, not recruiting | Drug: Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 520 | 2023-03-15 | Apr 2027 | ≤ 253 d | 2026-06-02 |
| MGNX | MacroGenics | $261M | A Study of Lorigerlimab in Participants With Advanced Solid TumorsNCT06730347Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as determined by the investigator | Phase 2 | Recruiting | Biological: Lorigerlimab | Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary, Clear Cell Adenocarcinoma of Vulva, Clear Cell Adenocarcinoma of Vagina, Clear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Uterus, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Peritoneum, Endometrial Cancer | 80 | 2025-05-01 | Jul 2027 | ≤ 345 d | 2026-06-02 |
| LLY | Eli Lilly and Company | $1.15T | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)NCT04956640Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy | Phase 1/2 | Active, not recruiting | Drug: LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin | Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms | 540 | 2021-07-19 | Apr 2027 | ≤ 253 d | 2026-05-29 |
| AZN | AstraZeneca | — | A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian FederationNCT05918042observationalTo describe the demographic and clinical characteristics of the patient population with HRD-positive OC (HRD+ BRCAwt and HRD+ BRCAm) | — | Completed | — | Ovarian Cancer | 414 | 2023-06-21 | 2025-05-29actual | — | 2026-05-28 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsNCT06238479Phase 1a: To determine the recommended dose of LY4101174 | Phase 1 | Active, not recruiting | Drug: LY4101174 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 490 | 2024-03-05 | Mar 2027 | ≤ 223 d | 2026-05-22 |
| AGEN | Agenus Inc. | $339M | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalNCT06751524expanded access | — | Available | Drug: Botensilimab, Balstililmab | Colorectal Cancer (CRC), Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC), Hepatocellular Carcinoma (HCC), Melanoma, Sarcoma, Ovarian Cancer, Prostate Cancer | — | — | — | — | 2026-05-15 |
| PFE | Pfizer | $155.3B | PF-07104091 as a Single Agent and in Combination TherapyNCT04553133Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle | Phase 2 | Active, not recruiting | Drug: PF-07104091 monotherapy dose escalation, PF-07104091 + palbociclib + fulvestrant, PF-07104091 + palbociclib + letrozole, PF-07104091 monotherapy dose expansion (ovarian), PF-07104091 monotherapy dose expansion (SCLC), PF-07104091 + Fulvestrant (post CDK4/6), PF-0704091 + Fulvestrant (post CDK4/6) | Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer | 157 | 2020-09-16 | 2026-12-31 | in 133 d | 2026-05-06 |
| IMNN | Imunon | $9M | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)NCT03393884PFS | Phase 1/2 | Active, not recruiting | Biological: IMNN-001 · Drug: Carboplatin, Paclitaxel | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 130 | 2018-09-05 | 2024-07-25actual | — | 2026-05-04 |
| TIL | Instil Bio | $50M | ITIL-306 in Advanced Solid TumorsNCT05397093Frequency and severity of ITIL-306 treatment-emergent adverse events (AEs), serious AEs, and AEs of special interest (AESI) | Phase 1 | Terminatedsponsor's stated reason: The study was terminated early due to discontinuation of development of the investigational program | Biological: ITIL-306 | Epithelial Ovarian Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma | 1 | 2022-08-24 | 2023-10-10actual | — | 2026-04-15 |
| AZN | AstraZeneca | — | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsNCT06973161observationalOverall Survival | — | Completed | — | Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Colorectal Cancer, Lung Cancer, Other Tumors | 140 | 2025-06-10 | 2026-03-17actual | — | 2026-04-08 |
| ZNTL | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | $264M | A Study of Azenosertib (ZN-c3) in Patients With Ovarian CancerNCT04516447Part 1: To investigate the safety and tolerability of azenosertib in combination with PLD, carboplatin, paclitaxel, or gemcitabine | Phase 1 | Recruiting | Drug: Azenosertib, Carboplatin, Pegylated liposomal doxorubicin, Paclitaxel, Gemcitabine · Biological: Bevacizumab | Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | 172 | 2020-10-26 | 2028-06-30 | in 680 d | 2026-04-07 |
| FATE | Fate Therapeutics | $307M | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsNCT07216105Number of participants with dose limiting toxicities (DLTs) | Phase 1 | Recruiting | Drug: FT836, Paclitaxel, Cetuximab, Trastuzumab | Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma | 113 | 2025-11-04 | Jan 2028 | ≤ 529 d | 2026-04-07 |
| AGEN | Agenus Inc. | $339M | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerNCT03860272Incidence Of Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Active, not recruiting | Drug: Botensilimab, Balstilimab | Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer | 499 | 2019-03-20 | 2025-01-13actual | — | 2026-03-30 |
| RADX | Radiopharm Theranostics, Ltd | — | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871Recommended dose(s) of 177Lu-BetaBart for future exploration (phase 1) | Phase 1/2 | Recruiting | Drug: 177Lu-BetaBart | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) | 61 | 2026-02-23 | Dec 2027 | ≤ 498 d | 2026-03-27 |
| ZNTL | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | $264M | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerNCT05198804To investigate the safety and tolerability of ZN-c3 in combination with niraparib, including identification of the MTD and RP2D | Phase 1/2 | Completed | Drug: Azenosertib, Niraparib | Ovarian Cancer, Platinum-resistant Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer | 117 | 2022-01-27 | 2025-10-15actual | — | 2026-03-18 |
| AZN | AstraZeneca | — | D9319C00001- 1L OC Mono Global RCTNCT04884360Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS in participants with Stage III/IV ovarian cancer with a BRCAwt HRD positive tumour and a CR/PR following standard 1st line platinum based chemotherapy treatment. | Phase 3 | Active, not recruiting | Drug: Olaparib · Other: Matching placebo | Ovarian Cancer | 366 | 2021-05-31 | 2026-07-27 | — | 2026-03-02 |
| PFE | Pfizer | $155.3B | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.NCT06546553PART 1: Number of participants with Dose-limiting toxicities (DLT) | Phase 1 | Terminatedsponsor's stated reason: Study terminated as part of strategic considerations and not based on safety concerns. | Drug: PF-07826390 · Biological: sasanlimab · Other: SOC (anti-PD-1 + platinum -based chemo) | Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma | 10 | 2024-09-06 | 2025-10-03actual | — | 2026-02-23 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersNCT06469281Incidence of treatment emergent adverse events (TEAEs) | Phase 1 | Recruiting | Other: 27T51 · Drug: Cemiplimab, Bevacizumab | Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer | 90 | 2024-08-06 | 2030-05-27 | in 1,376 d | 2026-02-03 |
| CUE | Cue Biopharma | $2.4B | A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic CancersNCT05360680Dose Limiting Toxicity | Phase 1 | Completed | Drug: CUE-102 | Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer | 42 | 2022-06-14 | 2025-03-12actual | — | 2026-01-22 |
| NTRA | Natera, Inc. | $44.9B | Sample Collection for Ongoing Research and Product Evaluation StudyNCT07318051observationalPrimary Outcome - Collection of Blood and Residual Tissue Specimens for Cancer Assay Development | — | Recruiting | — | Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer, Pancreatic Cancer, Ovarian Cancer, Gastroesophageal Cancer, Prostate Cancer, Melanoma, Head and Neck Cancer, Uterine Cancer, Liver Cancer | 9,600 | 2025-07-21 | Jan 2035 | ≤ 3,086 d | 2026-01-15 |
| NUVB | Nuvation Bio Inc. | $2.4B | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid TumorsNCT06334432Phase 1: Assess safety and tolerability of NUV-1511 in advanced solid tumors | Phase 1/2 | Active, not recruiting | Drug: NUV-1511 | Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC) | 466 | 2024-03-14 | Mar 2027 | ≤ 223 d | 2026-01-14 |
| ABBV | AbbVie | $457.5B | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube CancersNCT05041257results2026-01-09Objective Response Rate (ORR) Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1]) | Phase 2 | Completed | Drug: Mirvetuximab soravtansine | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 79 | 2021-10-19 | 2024-12-12actual | — | 2026-01-09 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsNCT05194072Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns | Drug: Felmetatug Vedotin, Pembrolizumab | Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma | 250 | 2022-01-12 | 2025-05-14actual | — | 2026-01-09 |
| STTK | Shattuck Labs, Inc. | $748M | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian CancersNCT05483933results2025-12-23Evaluate Safety and Tolerability of SL-172154 When Administered With PLD or Mirvetixumab | Phase 1 | Completed | Drug: Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154 | Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma | 86 | 2022-08-18 | 2025-02-07actual | — | 2025-12-23 |
| VSTM | Verastem, Inc. | $673M | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese PatientsNCT06682572Confirmed overall response rate (ORR; partial response [PR] + complete response [CR] | Phase 2 | Active, not recruiting | Drug: Avutometinib (VS-6766) + Defactinib (VS-6063) | Low Grade Serous Ovarian Cancer, Ovarian Cancer | 16 | 2024-10-30 | Dec 2025 | — | 2025-12-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Ovarian Cancer is matched — 26 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Ovarian Cancer
- Ovarian Neoplasms
- Epithelial Ovarian Cancer
- Ovarian Carcinoma
- Platinum-resistant Ovarian Cancer
- Advanced Ovarian Cancer
- Ovary Cancer
- Ovarian Clear Cell Carcinoma
- High Grade Serous Ovarian Cancer
- High Grade Serous Ovarian Carcinoma
- High-grade Serous Ovarian Cancer
- Ovarian Cancer, Epithelial
- Ovarian Epithelial Cancer
- Ovarian Neoplasm
- Ovary Neoplasm
- Platinum Resistant Ovarian Cancer
- Recurrent Ovarian Cancer
- Cancer - Ovarian
- Cancer of the Ovary
- Epithelial Ovarian Carcinoma
- Low Grade Ovarian Serous Adenocarcinoma
- Low Grade Serous Ovarian Cancer
- Low-grade Serous Ovarian Cancer
- Platinum-resistant Ovarian Cancer (PROC)
- Relapsed Ovarian Cancer
- Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Ovarian Cancer” (a text search, wider than this page)